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Aims Primary prevention studies have confirmed that high-density lipoprotein cholesterol (HDL-C) levels are strongly asso-
ciated with reduced cardiovascular events.However, recent evidence suggests that HDL-C functionality may be impaired
undercertain conditions. In thepresent study,wehypothesize thatHDL-Cmay lose their protective role in the secondary
prevention of coronary artery disease (CAD).
Methods
and results
A consecutive series of 1548 patients undergoing isolated first-time elective CABG at one institution between 2004 and
2009 was studied. According to the ATPIII criteria, pre-operative HDL-C values were used to identify patients with high
(Group A) vs. low HDL-C (Group B). To eliminate biased estimates, a propensity score model was built and two cohorts
of 1:1 optimally matched patients were obtained. Cumulative survival and major adverse cardiovascular events (MACE)
were analysed by means of Kaplan–Meier method. Cox proportional-hazards regression models were used to identify
independentpredictorsofMACEanddeath. Propensitymatching identified twocohortsof 502patients each.At amedian
follow-up time of 32 months, there were 44 out of 502 (8.8%) deaths in Group A and 36 out of 502 deaths in Group B
(7.2%, HR 1.19; P ¼ 0.42). MACE occurred in 165 out of 502 (32.9%) in Group A and 120 out of 502 (23.9%) in Group B
(P ¼ 0.04). Regression analysis showed that pre-operative HDL-C levels were not associated with reduced but rather
increased MACE occurrence during follow-up (HR 1.43, P ¼ 0.11).
Conclusion Higher HDL-C levels are not associated with reduced risk of vascular events in CAD patients undergoing CABG.
Our findings may support efforts to improve HDL-C functionality instead of increasing their levels.
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Introduction
Over the last few years, epidemiological studies have shown that low
high-density lipoprotein cholesterol (HDL-C) levels are associated
with an increased risk of coronary artery disease (CAD) and cardio-
vascular events.1,2 Indeed, low HDL-C remains an independent pre-
dictor of cardiovascular risk even in CAD patients with LDL
cholesterol levels , 70 mg/dL on statin therapy.3 Experimental
studies suggest that atheroprotective effects of HDL-C is based on
reverse cholesterol transport4,5 as well as anti-inflammatory proper-
ties.6 This led to the perspective that raising the levels of HDL-C
represents a potential therapeutic strategy to reduce cardiovascular
risk.7 However, recent translational studies strongly suggest that
vascular effects of HDL-C can be highly heterogeneous in different
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clinical conditions.8,9 HDL-C isolated from patients with CAD
showed less anti-inflammatory activity than HDL-C derived from
healthy controls.6 Furthermore, the capacity of HDL-C to stimulate
endothelial NO production and endothelial repair is substantially
reduced in patients with CAD and diabetes.10 The mechanisms
underlying this phenomenon remain to be fully elucidated but likely
include increased lipid oxidation of HDL-C due to a reduced
HDL-C-associated paroxonase-1 activity, an enzyme that protects
HDL-C from lipid oxidation, as well as modifications of the protein
moiety.11– 13
On the basis of these observations, the term ‘dysfunctional
HDL-C’ was coined to indicate the loss of their anti-inflammatory
and vasoprotectiveeffects.6 An increase of dysfunctional HDL-C par-
ticles may be less beneficial or might even be detrimental in certain
clinical settings. This issue needs to be rapidly clarified since therapies
that raise HDL-C levels are being investigated for the treatment of
CAD patients.14
In the present study, we evaluated the protective effect of HDL-C
cholesterol in a largeprospectivecohortofCADpatientsundergoing
elective coronary artery bypass grafting (CABG).
Our findings clearly show that protective effect of HDL-C choles-
terol is lost in secondary prevention of CAD suggesting that
HDL-C-raising strategies have to be carefully evaluated not to
exert counterproductive effects.
Methods
The study was reviewed and approved by the Institutional Review
Boardof the UniversityofRome, andawaiverof consentwas granted.
Patients and definitions
A consecutive series of patients undergoing isolated first-time elect-
ive CABG at one institution (Department of Cardiac Surgery, Ospe-
dale Sant’Andrea, Rome, Italy) between April 2004 and April 2009
was studied.
All the operations were performed through a full-median sternot-
omy on cardio-pulmonary bypass (CPB) and cardiac arrest was
obtained by means of antegrade cold-blood cardioplegia, repeated
every 15 min. The left internal mammary artery was always used to
graft the left anterior descending artery and revascularization com-
pleted using saphenous vein grafts to the right coronary and left cir-
cumflex artery segments.
Major adverse cardiovascular outcomes (MACE) were investi-
gated, including all-cause mortality, myocardial infarction, repeated
revascularization (either percutaneous or surgical), and cerebrovas-
cular accidents. Diagnosis of MI was made by clinical symptoms and
the presence of new Q waves, new persistent ST segment or
T-wave changes (Minnesota codes 1-1-1 to 1-2-7, 4-1, 4-2, 5-1, 5-2,
and 9-2), or elevated levels of troponin I. Diagnosis of stroke was
made if there was a clinical evidence or a focal/global defect on com-
puted tomography or magnetic resonance imaging.
Data were prospectively collected and recorded in an electronic
database and clinical follow-up was completed within routine out-
patient clinics. Patients who did not present at the visit were con-
tacted by telephone and all symptoms as well as any complications,
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Table 1 Baseline characteristics after propensity
matchinga
Group A
High HDL-C
Group B
Low HDL-C
P-value
Number of patients 502 502 N/A
Age, years 70+8 70+9 0.72
Gender, male, n (%) 388 (77.3) 386 (76.9) 0.55
Body mass index, kg/
m2
28.6+4.1 28.5+4.9 0.88
Hypertension, n (%) 476 (94.8) 477 (95.0) 0.59
Diabetes, n (%) 220 (43.8) 222 (44.2) 0.91
COPD, n (%) 178 (35.5) 181 (36.1) 0.64
History of smoking, n
(%)
286 (56.9) 285 (56.8) 0.82
Current smoking, n (%) 45 (8.9) 43 (8.6) 0.77
Pre-operative LVEF, % 52+10 51+11 0.64
Pre-operative GFR,
mL min21.1.73 m22
68+12 68+14 0.94
Pre-operative NYHA
class ≥ 3, n (%)
156 (31.1) 159 (31.7) 0.63
Pre-operative CCS
class ≥ 3, n (%)
307 (61.2) 304 (60.6) 0.52
Recent MI, n (%) 162 (32.3) 160 (31.9) 0.65
Previous stroke, n (%) 28 (5.6) 24 (5.0) 0.43
Pre-operative medications
ACE-inhibitors 340 (67.8) 341 (67.9) 0.78
ARBs 170 (33.9) 171 (34.1) 0.74
BBs 355 (70.7) 352 (70.1) 0.63
Statins 326 (64.9) 327 (65.1) 0.59
Ezetimibe 12 (2.4) 9 (1.8) 0.37
Fibrates 37 (7.4) 30 (5.9) 0.22
Diuretics 11 (11) 12 (12) 0.88
Insulin 124 (24.7) 126 (25.1) 0.69
Metformin 116 (23.1) 118 (23.5) 0.74
Sulfolynureas 31 (6.2) 32 (6.4) 0.82
LDL cholesterol, mg/
dL
124.3+39.6 122.9+45.3 0.55
HDL-C, mg/dL 52.6+18.7 36.4+12.3 ,0.0001
Triglycerides, mg/dL 132 (66–193)b 188 (100–
266)b
,0.0001
Logistic EuroSCORE
II, %
1.6 (0.4–5.1)c 1.7 (0.4–5.3)c 0.66
CPB time, min 86+22 87+24 0.41
X-Clamp time, min 58+19 59+21 0.57
Distal anastomoses,
mean
2.7+0.9 2.8+0.4 0.71
Continuous variables are expressed as mean+ standard deviation, categorical
variables as percentages.
GFR, glomerular filtration rate; NYHA, New York Heart Association; CCS,
Canadian Cardiovascular Society; MI, myocardial infarction; COPD, chronic
obstructive pulmonary disease; LVEF, left-ventricular ejection fraction; ACE,
angiotensin converting enzyme; ARB, angiotensin receptor blocker; BB,b-blockers;
CPB, cardio-pulmonary bypass; X-Clamp, aortic cross-clamp.
aGoodness-of-fit: c statistic 0.79, P ¼ 0.0001.
bValues shown are medians and interquartile ranges.
cValues shown are medians and their 95% confidence intervals.
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including mortality which occurred during the follow-up period were
recorded.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the
Social Sciences, version 11.0 (SPSS, Chicago, IL, USA). Variables were
checked for normality by means of the Kolmogorov–Smirnov test
for normal distribution and normality was accepted when P ≤ 0.05.
Continuous variables are shown as mean with standard deviation.
All categorical data were displayed as percentages. Differences in
baseline characteristics were compared using thex2 test for categor-
ical variables and t-test for continuous variables.
According to the ATPIII criteria,15 pre-operative values were used
to identify a group of high HDL-C (.50 mg/dL for women and
.40 mg/dL for men) vs. low HDL-C patients. To eliminate covariate
differences that might lead to biased estimates, a propensity score
model16 was built and two cohorts of 1:1 optimally matched patients
were obtained. The propensity score was computed with logistic re-
gression with the dependent variable being HDL-C class and the inde-
pendent variables (covariates) being age, gender, body mass index,
hypertension, diabetes, smoking status, pre-operative left-ventricular
ejection fraction (LVEF), pre-operative glomerular filtration rate
(GFR), recent MI, pre-operative angina and dyspnoea degrees
(NYHA and CCS classes), pre-operative stroke, medications (ACE-I,
ARB, BB, Diuretics, anti-glicemic agents, anti-lipemic agents), CPB
time, aortic cross-clamp time, and mean number of distal anastomoses;
mixingcontinuousandbinaryvariable toobtainasemi-saturatedmodel.
Cumulative survival and freedom from MACE at follow-up were
analysed by means of the Kaplan–Meier method and compared
between groups using a log-rank test.
The survival/freedom from event time of a patient started at the
time of surgery and ended at death/event or at last follow-up.
In addition, baseline characteristics showing a significant correl-
ation (P, 0.05)withendpoints atunivariate analysiswere then intro-
duced into two Cox proportional-hazards regression models to
identify independent predictors of both mortality and MACE at
follow-up. Age was the only continuous variable used, in fact, pre-
operative LVEF was dichotomized into LV dysfunction as ,0.41,
and pre-operative GFR (estimated with the four-variable Modified
Diet and Renal Disease equation)17 was dichotomized into pre-
operative renal dysfunction as ,61 mL min21.1.73 m22.
In addition, a sensitive analysis was performed using the full cohort
ofpatients rather than the propensity matched data.These results are
separately shown in the appendix.
Results
Based on ATPIII criteria, 1548 consecutive patients were divided into
patients with higher [617 (39.9%)] and with lower pre-operative
HDL-C [931 (60.1%)]. Propensity matching identified two cohorts
of 502 patients each, with high (Group A) vs. low (Group B) pre-
operative HDL-C. Table 1 depicts baseline characteristics stratified
for high or low HDL-C, after propensity matching. As shown, only
HDL-C and triglycerides levels were found to differ significantly
between the groups, thus allowing a fair comparison of outcomes. In
fact, the propensity model showed acceptable goodness-of-fit
(c statistic 0.79, P ¼ 0.0001) and discriminatory ability (x2 1.58,
significance 0.22). Median logistic EuroSCORE was 1.6 (95%CI 0.4–
5.1) for Group A and 1.7 (95%CI 0.4–5.3) for Group B (P ¼ 0.66).
Survival analysis
At a median follow-up time of 32 months (mean 29.1 months; 95%CI:
28.6–29.6 months), there were 44 out of 502 (8.8%) deaths among
high HDL-C patients and 36 out of 502 deaths among low HDL-C
patients (7.2%), hence survival curves (Figure 1) were similar
between high and low HDL-C groups: 87.0+ 2.2% for Group A vs.
88.1+ 2.1% for group B (Modelx2 0.66; HR 1.19; P ¼ 0.42). Further-
more, incidence of MACE was 165 out of 502 (32.9%) in Group A and
120 out of 502 (23.9%) in Group B, showing a statistically significant
difference (P ¼ 0.04), then confirmed at the Kaplan–Meier analysis
(Figure 2): freedom from MACE at 3 years was 57.0+ 2.8% for
Group A vs. 67.9+2.6% for Group B (Model x2 5.62; HR 1.32;
P ¼ 0.017).
Risk-factor analysis
A first Cox proportional-hazards regression model (x2 14.7,
P, 0.0001; Table 2) was built to identify independent predictors of
mortality: age (HR 1.15 per 1-year increase; P, 0.0001), diabetes
(HR 2.23, P ¼ 0.0002), chronic obstructive pulmonary disease (HR
1.74, P ¼ 0.03), and pre-operative renal dysfunction (HR 2.11,
P, 0.0001) were found to be independently correlated with sur-
vival. A trend towards worse survival was found among patients
with pre-operative LV dysfunction (HR 1.46, P ¼ 0.09), although it did
not reach statistical significance. Pre-operative HDL-C levels as well
were found to have some impact in increasing the risk of death (HR
1.33), but this correlation was not statistically significant (P¼ 0.13).
Independent predictors of MACE were identified by means of a
second Cox proportional-hazards regression model (x2 23.5, P,
0.0001; Table 3), which showed age (HR 1.36 per 1-year increase;
P, 0.0001), diabetes (HR 3.62, P, 0.0001), pre-operative renal
dysfunction (HR 1.94, P ¼ 0.03), pre-operative LV dysfunction (HR
Figure 1 Kaplan–Meier analysis of survival in patients with high
and low HDL-C.
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2.25, P ¼ 0.003), and pre-operative stroke (HR 2.18, P ¼ 0.02) to be
independently correlated with MACE-free survival of patients.
Chronic obstructive pulmonary disease did not show any correlation
with MACE-free survival (HR 1.07, P ¼ 0.14), while pre-operative
levels of HDL-C were found to have a negative impact on the occur-
rence of MACE during the follow-up (HR 1.43), but without reaching
statistical significance (P ¼ 0.11).
To further characterize the predictive value of HDL-C in our
population, an additional univariate analysis was performed among
the whole cohort of 1548 patients, before the propensity matching.
Variables showing significant association with mortality after un-
controlled univariate analysis were age (P ¼ 0.0001), diabetes
(P ¼ 0.0001), COPD (P ¼ 0.07), LVEF (P ¼ 0.001), GFR (P ¼
0.002), NYHA class (P ¼ 0.07), recent MI (P ¼ 0.02), CPB time
(P ¼ 0.01), and aortic cross-clamp time (P ¼ 0.01, Appendix, Table
A1). Similar results were found using MACE as a dependent variable.
In line with our propensity-based regression analysis, univariate ana-
lysis could not show any significant association between HDL-C and
either mortality or MACE (b ¼ 0.06, 95% CI: 20.11–0.27, P ¼
0.24). Independent variables significantly associated with death and
MACE were then included in the multivariate model (Table A2).
Age, diabetes, GFR, and LVEF were independently associated with
either death or MACE (Appendix, Table A2).
Discussion
The present study demonstrates that the well-known protective role
of HDL-C is lost in a large cohort of CAD patients undergoing iso-
lated first-time elective CABG.
Primary prevention studies have previously suggested a pivotal
role of HDL-C as a strong inverse predictor of cardiovascular
events.1,2 The HDL-C level in patients receiving statins were
indeed predictive of major cardiovascular events across the TNT
study cohort.3 Moreover, even among study subjects with LDL chol-
esterol levels below 70 mg per decilitre, those in the highest quintile
of HDL-C level were at less risk for major cardiovascular events than
those in the lowest quintile.2 Consistently, experimental observa-
tions showed unequivocal anti-atherogenic and anti-inflammatory
properties of HDL-C isolated from healthy subjects.6,18 The vaso-
protective effect of HDL-C is thought to relate to reverse macro-
phage cholesterol transport19 and, more recently, by the notion
that HDL-C warrants endothelial homeostasis via the increase in
nitric oxide production as well as the inhibition of critical pathways
involved in vascular inflammation and endothelial apoptosis.20 This
body of evidence led to consider the opportunity to raise HDL-C
levels as a potential therapeutic strategy to reduce cardiovascular
risk.21
Recent translational studies demonstrated that HDL-C isolated
from patients with CAD or diabetes lose their ability to stimulate
endothelial NO production and accelerate endothelial repair.20
The oxidative milieu observed in patients with CAD may lead to a
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Table 2 Cox proportional-hazards regression analysis
of time to deatha
Hazard
ratio
95% CI P-value
Age 1.15b 1.09–1.42 ,0.0001
Diabetes mellitus 2.23 1.52–3.67 0.0002
COPD 1.74 1.53–2.46 0.03
Pre-operative renal
dysfunction
2.11 1.62–3.55 ,0.0001
Pre-operative LV
dysfunction
1.46 0.94–2.11 0.09
High HDL-C 1.33 0.86–1.64 0.13
LV, left ventricular; HDL, high-density lipoprotein; COPD, chronic obstructive
pulmonary disease.
aModel x2 14.7; P, 0.0001.
bPer 1-year increase.
Figure 2 Kaplan–Meier curves showing MACE-free survival in
patients with high and low HDL-C.
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Table 3 Cox proportional-hazards regression analysis
of time to major adverse cardiovascular eventa
Hazard
ratio
95% CI P-value
Age 1.36b 1.19–1.53 ,0.0001
Diabetes mellitus 3.62 1.81–4.25 ,0.0001
Chronic obstructive
pulmonary disease
1.07 0.88–2.06 0.14
Pre-operative renal
dysfunction
1.94 1.62–2.15 0.03
Pre-operative LV dysfunction 2.25 1.67–2.83 0.003
Pre-operative stroke 2.18 1.62–2.96 0.02
High HDL-C 1.43 0.89–2.07 0.11
LV, left ventricular; HDL, high-density lipoprotein.
aModel x2 23.5; P, 0.0001.
bPer 1-year increase.
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deregulation of critical enzymes protecting HDL-C from oxidation.4
However, it is not clear whether modifications of HDL-C structure
and functionality translate in a loss of their protectiveeffect in the sec-
ondary prevention of cardiovascular disease. This aspect deserves at-
tention since therapies that raiseHDL-C levels are in high demand for
the secondary prevention of CAD.14 In the present study, we inves-
tigated the possibility that HDL-C may not be protective against
future cardiovascular events in CAD patients undergoing surgical
revascularization with CABG. To this end, in our study population,
pre-operative HDL-C values were used to identify two groups of
high and low HDL-C patients according to ATPIII criteria. In order
to rule out the confounding effect of covariates, a propensity score
model was built and two cohorts of optimally matched 1:1 patients
were obtained. Cox proportional-hazard regression models
showed that all-cause mortality rate was 8.8 and 7.2% in high and
low HDL-C groups (HR 1.33, P ¼ 0.13), respectively. More interest-
ingly, a similar trend was observed when considering MACE occur-
rence. Indeed, pre-operative values of HDL-C were found to
directly correlate with cardiovascular events (HR 1.43) but without
reaching statistical significance (P ¼ 0.11). Moreover, uncontrolled
univariate and multivariate analysis performed on the whole popula-
tion of 1548 patients before propensity matching confirmed the lack
of a protective effect of HDL-C (b ¼ 0.06, 95% CI: 20.11–0.27,
P ¼ 0.24). These results suggest that the inverse relation between
HDL-C and cardiovascular mortality may be overturned in patients
with CAD. Indeed, patients with higher HDL-C showed a clear
trend towards increased all-cause mortality and cardiovascular
event rates. Hence, the present analysis strengthens the notion that
raising dysfunctional HDL-C may be potentially detrimental in
CAD patients.22– 26 In the present study, the propensity-based ana-
lysis explored the relation between HDL-C levels and cardiovascular
events ruling out the effect of confounding factors such as age, dia-
betes, previous cardiovascular events as well as pre-operative renal
and LV dysfunction. Logistic EuroSCORE II, CPB time, X-Clamp
time, and number of distal anastomoses were also equally distributed
among the two groups, thus excluding the impact of different revas-
cularization modalities. Importantly, treatment with statins, ezeti-
mibe, and fibrates did not differently affect HDL-C levels during
follow-up.
The main limitation of the present study is the retrospective
nature. Despite the use of propensity score analysis to control for se-
lectionbias, eventually unidentifiedconfoundersmayhave influenced
the results. Moreover, statin use is suboptimal in our population and
our findings may not be generalizable to every cohort of CABG
patients. However, propensity matching allowed a similar distribu-
tion of lipid-lowering agents among patients with high and low
HDL-C.
In conclusion, we show here that higher HDL-C levels are not
associated with a reduced risk of vascular events in patients with
CAD undergoing elective bypass surgery. Our findings suggest that
HDL-C functionality may be impaired in patients with CAD and
may support efforts to improve HDL-C functionality instead of
increasing their levels.
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Appendix
To deeply investigate the relationship between HDL-cholesterol and
outcomes among CABG patients, a sensitive analysis on the whole
cohort of patients was performed.
To identify baseline factors correlated to the endpoints investi-
gated, univariate Cox proportional-hazards regression was used.
With respect to mortality (Table A1), variables showing significant
(P, 0.1) association were age (P, 0.0001), diabetes (P,
0.0001), COPD (P ¼ 0.05), pre-operative LV dysfunction (P ¼
0.003), pre-operative renal dysfunction (P ¼ 0.0001), pre-operative
NYHA class ≥ 3 (P ¼ 0.04), and pre-operative recent MI (P ¼
0.08). Similar results were found using MACE as dependent variable.
Moreover, a multivariable Cox proportional-hazards regression
model was used to identify independent predictors of mortality
using all variables showing a significant correlation at univariable ana-
lysis (P, 0.10).
Multivariable Cox regression analysis (Table A2) showed age
(P ¼ 0.0001), diabetes (P ¼ 0.01), LV dysfunction (P ¼ 0.03), and
renal dysfunction (P ¼ 0.001) to be independent predictors of mortal-
ity, while age (P, 0.0001), diabetes (P ¼ 0.0001), COPD (P ¼ 0.04),
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Table A1 Univariate analysis of correlation between
baseline characteristics and mortality among the whole
cohort of patients
HR 95% CI P-value
Age 1.19a 1.10–1.55 ,0.0001
Male gender 1.22 1.05–1.63 0.12
Body mass index 1.16 20.53–1.67 0.16
Hypertension 1.36 1.20–1.69 0.14
Diabetes 2.25 1.71–3.42 ,0.0001
COPD 1.82 1.54–2.49 0.05
History of smoking 1.63 1.22–2.15 0.16
Current smoking 1.75 1.25–2.51 0.12
Pre-operative LV dysfunction 1.77 1.64–2.37 0.003
Pre-operative renal dysfunction 2.36 1.81–4.10 0.0001
Pre-operative NYHA class ≥ 3 1.74 1.56–1.82 0.04
Pre-operative CCS class ≥ 3 1.32 1.04–1.66 0.45
Recent MI 1.58 1.16–1.92 0.08
Previous stroke 1.51 1.02–2.01 0.22
High HDL-C 1.27 20.34–1.59 0.18
CPB time 1.26 1.01–1.42 0.11
X-Clamp time 1.22 1.04–1.39 0.13
NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; MI,
myocardial infarction; COPD, chronic obstructive pulmonary disease; LV, left
ventricular; CPB, cardio-pulmonary bypass; X-Clamp, aortic cross-clamp.
aPer 1-year increase.
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LV dysfunction (P ¼ 0.002), and renal dysfunction (P ¼ 0.001) were
found to be independent predictors of MACE.
Both Cox regression models significantly predicted their out-
comes (model x2 ¼ 21.6; P, 0.0001 for mortality model; model
x2 ¼ 24.8; P, 0.0001 for MACE model).
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Table A2 Cox proportional-hazards regression
analysis of pre-operative variables for each endpoint
Endpoints Variables HR 95% CI P-value
Mortality
Age 1.22a 1.11–1.63 0.0001
Diabetes 2.37 1.61–3.82 0.01
COPD 1.68 1.22–4.17 0.08
LV dysfunction 1.66 1.88–2.35 0.03
Renal dysfunction 2.74 1.95–5.13 0.001
NYHA class ≥ 3 1.57 1.16–2.71 0.09
Recent MI 1.26 1.05–1.63 0.18
High HDL-C 1.29 21.02–1.61 0.26
Major adverse cardiovascular events
Age 1.41a 1.25–1.76 ,0.0001
Diabetes 2.45 1.73–4.14 0.0001
COPD 1.71 1.55–4.19 0.04
LV dysfunction 1.82 1.74–2.66 0.002
Renal dysfunction 2.16 1.85–3.87 0.001
NYHA class ≥ 3 1.34 1.19–1.49 0.22
Recent MI 1.11 1.03–1.46 0.47
High HDL-C 1.31 21.02–1.63 0.19
HR, hazard ratio; CI, confidence interval; NYHA, New York Heart Association; MI,
myocardial infarction; COPD, chronic obstructive pulmonary disease; LV, left
ventricular.
aPer 1-year increase.
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